While Amgen's (NASDAQ: AMGN) shares have underperformed the market over the past 12 months, climbing 19.7% compared to the ...
As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
1don MSN
The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded ...
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...
A hidden tab in an Excel spreadsheet published nine months ago has wiped $12 billion off Amgen’s market cap. The tab ...
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, ...
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Amgen (NasdaqGS:AMGN) with a Peer Perform ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback